|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial显示文摘 | Ronald P DeMatteo Karla V Ballman Cristina R Antonescu Robert G Maki Peter WT Pisters George D Demetri Martin E Blackstein Charles D Blanke Margaret von Mehren Murray F Brennan Shreyaskumar Patel Martin D McCarter Jonathan A Polikoff Benjamin R Tan Kouros | 2009 | The Lancet2009，，9669： | 2 |
| 2 | Indications and surgical options for small bowel, large bowel and perianal Crohn's disease显示文摘Despite advancements in medical therapy of Crohn's disease(CD), majority of patients with CD will eventually require surgical intervention, with at least a third of patients requiring multiple surgeries. It is important to understand the role and timing of surgery, with the goals of therapy to reduce the need for surgery without increasing the odds of emergency surgery and its associated morbidity, as well as to limit surgical recurrence and avoid intestinal failure. The profile of CD patients requiring surgical intervention has changed over the decades with improvements in medical therapy with immunomodulators and biological agents. The most common indication for surgery is obstruction from stricturing disease, followed by abscesses and fistulae. The risk of gastrointestinal bleeding in CD is high but the likelihood of needing surgery for bleeding is low. Most major gastrointestinal bleeding episodes resolve spontaneously, albeit the risk of re-bleeding is high. The risk of colorectal cancer associated with CD is low. While current surgical guidelines recommend a total proctocolectomy for colorectal cancer associated with CD, subtotal colectomy or segmental colectomy with endoscopic surveillance may be a reasonable option. Approximately 20%-40% of CD patients will need perianal surgery during their lifetime. This review assesses the practice parameters and guidelines in the surgical management of CD, with a focus on the indications for surgery in CD(and when not to operate), and a critical evaluation of the timing and surgical options available to improve outcomes and reduce recurrence rates. | James WT Toh Peter Stewart Matthew JFX Rickard Rupert Leong Nelson Wang Christopher J Young | 2016 | World Journal of Gastroenterology2016，22，40： | 2 |
| 3 | 重组脊髓灰质炎病毒用于治疗复发胶质母细胞瘤(英文)显示文摘Background The prognosis of patients with recurrent World Health Organization(WHO)grade IV malignant glioma is dismal,and there is currently no effective therapy.We conducted a dose-finding and toxicity study in this population of patients,evaluating convection-enhanced,intratumoral delivery of the recombinant nonpathogenic polio-rhinovirus chimera(PVSRIPO).PVSRIPO recognizes the poliovirus receptor CD155,which is widely expressed in neoplastic cells of solid tumors and in major components of the tumor microenvironment.Methods We enrolled consecutive adult patients who had recurrent supratentorial WHO grade IV malignant glioma,confirmed on histopathological testing,with measurable disease(contrast-enhancing tumor of≥1 cm and≤5.5 cm in the greatest dimension).The study evaluated seven doses,ranging between 107 and 1010 50%tissue-culture infectious doses(TCID50),first in a dose-escalation phase and then in a dose-expansion phase.Results From May 2012 through May 2017,a total of 61 patients were enrolled and received a dose of PVSRIPO.Dose level-1(5.0×107TCID50)was identified as the phase 2 dose.One dose-limiting toxic effect was observed;a patient in whom dose level 5(1010TCID50)was administered had a grade 4 intracranial hemorrhage immediately after the catheter was removed.To mitigate locoregional inflammation of the infused tumor with prolonged glucocorticoid use,dose level 5 was deescalated to reach the phase 2 dose.In the dose-expansion phase,19%of the patients had a PVSRIPO-related adverse event of grade 3 or higher.Overall survival among the patients who received PVSRIPO reached a plateau of 21%(95%confidence interval,11 to 33)at 24 months that was sustained at 36 months.Conclusions Intratumoral infusion of PVSRIPO in patients with recurrent WHO grade IV malignant glioma confirmed the absence of neurovirulent potential.The survival rate among patients who receivedPVSRIPO immunotherapy was higher at 24 and 36 months than the rate among historical controls. | Desjardins A Gromeier M Herndon JE 2nd Beaubier N Bolognesi DP Friedman AH Friedman HS McSherry F Muscat AM Nair S Peters KB Randazzo D Sampson JH Vlahovic G Harrison WT McLendon RE Ashley D Bigner DD | 2018 | 中华神经外科疾病研究杂志2018，17，4： | 2 |
| 4 | Retroperitoneal Sarcomas 显示文摘 | Christopher WT Peter WT | 2005 | Cancer Control2005，1，： | 1 |
| 5 | Retroperitoneal Sarcomas 显示文摘 | Christopher WT Peter WT Pisters | 2005 | Cancer Control2005，1，： | 1 |
| 6 | Autologous spleen transplantation for spleen trauma显示文摘 | Peter WT | 1994 | Ann Surg1994，219，： | 1 |
| 7 | 27-O-demethyl- rapamycin, an immunosuppressant compound produced by a new strain of Streptomyces hygroscopicus 显示文摘 | Stephen JB Peter RS John WT | 1995 | J Antibiot (Tokyo)1995，48，11： | 1 |
| 8 | Retroperitoneal Sarcomas显示文摘 | Christopher WT Peter WT Pisters | 2005 | Cancer Contro2005，1，： | 1 |
| 9 | Epidemiology of severe sepsis in the United States:analysis of incidence,outcome,and associated costs of care 显示文摘 | Peter C Angus DC Linde-Zwirble WT | 2001 | Crit Care Med2001，29，： | 1 |
| 10 | The learning curve in pancreatic surgery显示文摘 | Tseng JF Pisters Peter WT Lee JE | | 0，，： | 1 |
| 11 | Retroperitoneal sarcomas:combined modality treatment approaches显示文摘 | Peter WT Pisters Brian O'Sullivan | 2002 | Curre Opin Onto2002，14，4： | 1 |
| 12 | Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial显示文摘 | Ronald P DeMatteo Karla V Ballman Cristina R Antonescu Robert G Maki Peter WT Pisters George D Demetri Martin E Blackstein Charles D Blanke Margaret von Mehren Murray F Brennan Shreyaskumar Patel Martin D McCarter Jonathan A Polikoff Benjamin R Tan Kouros | 2009 | The Lancet2009，，9669： | 1 |
| 13 | Enhancement of Detection Efficiency for Minute Signals Embedded in Large Background Using Non-stantionarity显示文摘 | Peter WT Yuen | 2000 | Underwater Defence Technology Proceeding 05-00-UDT-1502000，，： | 1 |
| 14 | Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial显示文摘 | Ronald P DeMatteo Karla V Ballman Cristina R Antonescu Robert G Maki Peter WT Pisters George D Demetri Martin E Blackstein Charles D Blanke Margaret von Mehren Murray F Brennan Shreyaskumar Patel Martin D McCarter Jonathan A Polikoff Benjamin R Tan Kouros | 2009 | The Lancet2009，，9669： | 1 |
| 15 | Evidence for a role of intrauterine infections in the pathogenesis of cystic ovaries in postpartum dairy cows显示文摘 | Bosu WT Peter AT | | 0，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员